631 Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ

Christoph Bucher; Guzman Alonso; Juanita Lopez; Emiliano Calvo; Markus Joerger; Vicky Sanchez Perez; Elena Corral; Daniela Di Blasi; Kirsten Richter; Christoph Huber; Julie Mouton; Silvio Costanzo; Sangeeta Jethwa; Elena Gerralda; Heinz Läubli

doi:10.1136/jitc-2022-SITC2022.0631

Article info

Regular and Young Investigator Award Abstracts

Clinical Trials In Progress

631 Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ

Free

Authors

Christoph Bucher Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Guzman Alonso Vall d’Hebron, Barcelona, Spain PubMed articles Google scholar articles
Juanita Lopez Royal Marsden, London, UK PubMed articles Google scholar articles
Emiliano Calvo START Madrid-CIOCC, Madrid, Spain PubMed articles Google scholar articles
Markus Joerger Kantonsspital St. Gallen, St. Gallen, Switzerland PubMed articles Google scholar articles
Vicky Sanchez Perez Royal Marsden, London, UK PubMed articles Google scholar articles
Elena Corral START Madrid-CIOCC, Madrid, Spain PubMed articles Google scholar articles
Daniela Di Blasi Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Kirsten Richter Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Christoph Huber Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Julie Mouton Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Silvio Costanzo Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Sangeeta Jethwa Anaveon AG, Basel, Switzerland PubMed articles Google scholar articles
Elena Gerralda Vall d’Hebron, Barcelona, Spain PubMed articles Google scholar articles
Heinz Läubli University Hospital, Basel, Switzerland PubMed articles Google scholar articles

Citation

Bucher C, Alonso G, Lopez J, et al

631 Phase I dose escalation study in patients with advanced solid tumors with ANV419, a novel fusion protein selective for IL-2Rβ/γ

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0631

Publication history

First published November 7, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password